Clinical Trial Update: Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating intravitreal ranibizumab as adjuvant therapy for postvitrectomy diabetic vitreous hemorrhage with neovascular glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy
• Glaucoma
• Neovascular Glaucoma

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Diabetic Retinopathy, Glaucoma, Neovascular | Phase 4 | Status: COMPLETED